INmune Bio (NASDAQ:INMB) Posts Earnings Results

INmune Bio (NASDAQ:INMB) posted its quarterly earnings results on Thursday. The company reported ($0.05) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.21) by $0.16, Zacks reports.

Here are the key takeaways from INmune Bio’s conference call:

• Positive Sentiment: INmune Bio expects to submit Ebstrocel’s U.K. marketing authorization application by the end of Q3 or early Q4 2026, followed by EMA and U.S. submissions in early 2027. MHRA alignment across clinical, non-clinical, and CMC requirements, plus approval of the pediatric investigation plan, reduces regulatory uncertainty.
• Positive Sentiment: Ebstrocel manufacturing and supply-chain readiness advanced, including commercial-ready cord-tissue processing, transfer of MSC isolation to the intended commercial facility, and expanded access to umbilical cord tissue through Anthony Nolan. Management believes this supports scalable supply for potential U.K., European, and U.S. commercialization.
• Positive Sentiment: XPro received FDA Fast Track designation for early Alzheimer’s disease, while the MINDFuL Phase II study showed statistically significant improvement in white-matter myelin MRI biomarkers. Management is advancing a registrational strategy and evaluating partnerships, although Alzheimer’s remains the clinical priority.
• Neutral Sentiment: The company reported $18.4 million in cash at June 30 and received a subsequent $4.2 million Australian R&D rebate, with funding expected to last into Q2 2027. Management estimates a forward burn rate of roughly $1 million to $1.5 million per month and expects to raise capital selectively, but future financing could still create dilution.
• Positive Sentiment: If approved, management estimates a U.K. opportunity of roughly 800 RDEB patients and anticipates pricing of approximately £400,000–£500,000 per child annually, subject to reimbursement negotiations. The company also highlighted a potential U.S. rare pediatric disease priority review voucher, which it estimates could be worth $100 million to $200 million, though neither approval nor monetization is assured.

INmune Bio Price Performance

NASDAQ:INMB traded up $0.01 during mid-day trading on Thursday, hitting $1.91. The company’s stock had a trading volume of 233,316 shares, compared to its average volume of 561,200. INmune Bio has a 1 year low of $1.09 and a 1 year high of $2.85. The stock has a market cap of $50.77 million, a price-to-earnings ratio of -1.14 and a beta of 0.97. The business’s fifty day moving average is $1.61 and its two-hundred day moving average is $1.47.

Analyst Upgrades and Downgrades

Several equities analysts recently issued reports on the company. Weiss Ratings downgraded INmune Bio from a “sell (d-)” rating to a “sell (e+)” rating in a research report on Wednesday. Wall Street Zen cut INmune Bio from a “hold” rating to a “sell” rating in a research report on Saturday, July 25th. One research analyst has rated the stock with a Strong Buy rating and one has issued a Sell rating to the stock. Based on data from MarketBeat, INmune Bio currently has an average rating of “Moderate Buy”.

Institutional Inflows and Outflows

Institutional investors have recently bought and sold shares of the stock. Quadrature Capital Ltd acquired a new position in INmune Bio in the fourth quarter valued at approximately $26,000. Intech Investment Management LLC acquired a new stake in shares of INmune Bio during the 2nd quarter worth approximately $26,000. Squarepoint Ops LLC purchased a new position in shares of INmune Bio during the 3rd quarter valued at approximately $30,000. Virtu Financial LLC purchased a new position in shares of INmune Bio during the 4th quarter valued at approximately $32,000. Finally, Wells Fargo & Company MN lifted its stake in shares of INmune Bio by 79.0% in the 4th quarter. Wells Fargo & Company MN now owns 24,857 shares of the company’s stock valued at $39,000 after purchasing an additional 10,970 shares during the period. 12.72% of the stock is currently owned by hedge funds and other institutional investors.

INmune Bio Company Profile

INmune Bio, Inc is a clinical-stage immunology company based in San Diego, California, focused on harnessing the innate immune system to combat a range of serious diseases. The company’s research and development efforts concentrate on modulating cellular pathways to restore and enhance the body’s natural defenses, particularly in oncology and neurodegenerative conditions.

The company’s lead therapeutic candidate, XPro1595 (also referred to as INB03), is a proprietary selective inhibitor of soluble tumor necrosis factor (TNF) designed to reduce chronic inflammation without impairing membrane-bound TNF functions.